Results 151 to 160 of about 145,099 (296)

Atypical chronic lymphocytic leukemia with biallelic 13Q deletion. [PDF]

Hematol Transfus Cell Ther
Roldán Galiacho V, Altuna Tellechea L, Alonso Varela M, Diez de Lezcano Manrique deLara I.   +3 more
europepmc   +1 more source

Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements

Molecular Carcinogenesis, EarlyView.
ABSTRACT Radiotherapy (RT) has evolved significantly since its inception from treating benign conditions to becoming a cornerstone of cancer treatment. This review examines the complex interactions between RT and the immune system, highlighting its diverse effects on various immune cell populations, and exploring emerging strategies to enhance ...
Safiy Yahia, Ayman J. Oweida, Houda Bahig, Daniel Taussky   +3 more
wiley   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, EarlyView.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

B-Cell Chronic Lymphocytic Leukemia in a Cat. [PDF]

Vet Clin Pathol
Mori JA, Stacey E, El Helou Y, Bienzle D.   +3 more
europepmc   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Hypertension affects survival and treatment in chronic lymphocytic leukemia. [PDF]

Blood Adv
Vainer N, Brieghel C, Rostgaard K, Davíðsson ÓB, Dietz JB, Frederiksen CM, da Cunha-Bang C, Hjalgrim H, Niemann CU, Rotbain EC.   +9 more
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Specific Lipidomic Shifts in Chronic Lymphocytic Leukemia at Diagnosis. [PDF]

Cancers (Basel)
Wojnicka J, Kiełbus M, Mertowska P, Mertowski S, Grywalska E, Sosnowski P, Wielgosz A, Kozub-Pędrak A, Sosnowska-Pasiarska B, Klatka M, Klatka J, Błażewicz A.   +11 more
europepmc   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Cost of Serious Infections in Chronic Lymphocytic Leukemia. [PDF]

Cancer Med
Carrillo de Albornoz S, Arnolda R, Higgins AM, Wood EM, McQuilten ZK, Petrie D.   +5 more
europepmc   +1 more source